| Bioactivity | IR820-PTX, an IR-820 (HY-136886)-Paclitaxel (HY-B0015) conjugate, is an amphipathic small molecule prodrug. IR820-PTX effectively inhibits tumor growth via combined photothermal therapy (PTT) and chemotherapy[1][2]. |
| Name | IR820-PTX |
| CAS | 2250419-19-1 |
| Formula | C99H112N4NaO21S2+ |
| Molar Mass | 1781.08 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang D, et al. pH- and Enzyme-Sensitive IR820-Paclitaxel Conjugate Self-Assembled Nanovehicles for Near-Infrared Fluorescence Imaging-Guided Chemo-Photothermal Therapy. ACS Appl Mater Interfaces. 2018 Sep 12;10(36):30092-30102. [2]. Yu-Xia Luan, et al. Preparation method and application of amphiphilic small molecule prodrug of ir820-ptx combined with photothermal therapy and chemotherapy and its nanoparticles. CN108727353B. |
IR820-PTX
CAS: 2250419-19-1 F: C99H112N4NaO21S2+ W: 1781.08
IR820-PTX, an IR-820 (HY-136886)-Paclitaxel (HY-B0015) conjugate, is an amphipathic small molecule prodrug. IR820-PTX ef
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.